GSK Responds to Patent Ruling Reversal on Lovaza
GSK reported that the Court of Appeals has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza.
GlaxoSmithKline (GSK) reported that a US federal appeals court has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza (omega-3-acid ethyl esters). The Lovaza patents are owned by Pronova and licensed to GSK. The patents relate to compositions and methods of using omega-3 fatty acids. GSK has marketing rights for Lovaza in the US and Puerto Rico. Reversing a lower court ruling, the appellate court found the asserted claims of Pronova’s patent (US Patent 5,656,667) invalid and remanded the case to the district court with orders to enter judgment in favor of the appellant Abbreviated new drug application filers.
The Lovaza patents are owned by Pronova and licensed to GSK. The patents relate to compositions and methods of using omega-3 fatty acids. GSK has marketing rights for Lovaza in the US and Puerto Rico.
Lovaza remains available, and GSK is not aware that FDA has approved any generic versions to date.
Source: GlaxoSmithKline
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
